What is the financial impact of Mr. Ayers's departure and transition?

IDEXX Laboratories expects to recognize a charge of approximately $13 million in the fourth quarter of 2019. This charge covers severance payments to Mr. Ayers, including base salary continuation and medical coverage, as well as the acceleration of costs associated with modifications to his outstanding stock options.

What are the terms of Mr. Ayers's new role as Senior Advisor?

As an external Senior Advisor, Mr. Ayers will provide advice and services on matters agreed upon with the CEO. He will receive advisory fees of $240,000 per year, payable in quarterly installments. This role is not for a specific term and can be terminated by either party with 90 days' notice.

What is the compensation structure for the new CEO, Jay Mazelsky?

Mr. Mazelsky's new employment agreement includes an annual base salary of $850,000, an annual bonus opportunity targeted at 125% of his base salary, and significant equity grants. He is set to receive an initial stock option grant valued at approximately $2 million and potentially another grant valued at approximately $4 million in early 2020.

What are the severance provisions for CEO Jay Mazelsky?

If terminated by the Company without 'Cause' (outside of a Change of Control Period), Mr. Mazelsky is entitled to two years of base salary continuation, two years of employer-paid medical coverage continuation, and continued vesting of equity awards during the severance period. In the event of termination without Cause or resignation for 'Good Reason' within 24 months of a 'Change of Control,' he is entitled to a lump sum payment equal to three times his base salary plus average annual bonuses, three years of medical coverage continuation, and full vesting of all unvested equity awards.

IDXX 8-K: Leadership Changes & Regulation FD

Summary

IDEXX Laboratories, Inc. (IDXX) has announced significant leadership changes via an 8-K filing on October 24, 2019. Jonathan W. Ayers, the former Chairman and CEO, will transition out of his executive role on November 1, 2019, moving to an external Senior Advisor position and remaining on the Board. This transition follows a medical leave initiated in June 2019. Concurrently, the Board has appointed Jonathan (Jay) Mazelsky as the permanent President and Chief Executive Officer, a role he has held on an interim basis since June 2019. Mr. Mazelsky has also been elected to the Board, and Lawrence D. Kingsley has been appointed Independent Non-Executive Chairman, effective November 1, 2019. The company has entered into separation and advisory agreements with Mr. Ayers, which include salary continuation, medical coverage support, and arrangements for his unvested stock options. These agreements, along with the terms of Mr. Mazelsky's new employment, will result in an estimated $13 million charge in the fourth quarter of 2019, primarily related to severance and equity award modifications for Mr. Ayers. Investors should note the financial implications of these leadership transitions and the details of the new CEO's compensation package, which includes a substantial base salary, bonus opportunity, and significant equity grants.

Key Highlights

1Jonathan W. Ayers transitions from Chairman and CEO to external Senior Advisor and Board member, effective November 1, 2019.
2Jonathan (Jay) Mazelsky is appointed permanent President and CEO, effective October 23, 2019, and elected to the Board.
3Lawrence D. Kingsley is appointed Independent Non-Executive Chairman, effective November 1, 2019.
4Mr. Ayers will receive approximately $1.6 million in base salary continuation over two years and continued medical coverage.
5Mr. Ayers's unvested stock options will continue to vest, and all options will remain exercisable without continued service requirement.
6The company anticipates a Q4 2019 charge of approximately $13 million related to Mr. Ayers's severance and equity award modifications.
7Mr. Mazelsky's new employment agreement includes an annual base salary of $850,000, a target bonus of 125% of base salary, and significant equity grants valued at approximately $6 million (initial grant + potential additional grant).

IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Oct 24, 2019)

Summary

Key Highlights

Frequently Asked Questions